Neurology(R) neuroimmunology & neuroinflammation · 2026
Application of Optic Neuritis Diagnostic Criteria in Autoimmune Paraneoplastic CRMP5 Optic Neuropathy and Development of the "CRMP" Score.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dinoto Alessandro, Cohen Devon A, Cacciaguerra Laura, Tisavipat Nanthaya, Syc-Mazurek Stephanie B, Lennon Vanda A, Bhatti M Tariq, Tajfirouz Deena A, Chodnicki Kevin D, Pittock Sean J, Flanagan Eoin P, Chen John J
Аннотация
OBJECTIVES: Collapsin response-mediator protein 5 (CRMP5)-IgG is an acknowledged biomarker in the International Consortium on Optic Neuritis (ICON) diagnostic criteria for optic neuritis (ON), but these criteria have not been validated in CRMP5-IgG+ON.
METHODS: We evaluated the ICON and Acute Optic Neuritis Network (ACON) criteria for CRMP5-IgG+ON, using patients with late-onset (age ≥50 years) aquaporin-4-IgG-positive (AQP4-IgG+)-ON or myelin-oligodendrocyte glycoprotein antibody (MOG-IgG+)-ON for comparison. We developed the "CRMP score," based on typical CRMP5-IgG+ON clinical features, to guide CRMP5 antibody testing in ON.
RESULTS: The study included 17 patients with CRMP5-IgG+, 11 with AQP4-IgG+ON, and 13 with MOG-IgG+ON. Application of ICON criteria yielded no "definite ON" and 1 "probable ON" diagnosis among the 17 CRMP5-IgG+ cases, but definite ON diagnoses for 6 of 11 AQP4-IgG+ (55%, p = 0.003) and 7 of 13 MOG-IgG+ cases (54%, p = 0.001). ACON criteria yielded definite ON diagnoses for 2 (12%) CRMP5-IgG+ON, 10 (91%) of the AQP4-IgG+ON, and 13 (100%) of the MOG-IgG+ON (p < 0.001). A CRMP score ≥1 identified CRMP5-IgG+ON with a sensitivity of 88.2% and a specificity of 87.5%.
DISCUSSION: ICON and ACON criteria for ON diagnosis identified only a minority of CRMP5-IgG+ON cases; thus, we developed the "CRMP" score to aid their identification in clinical practice.
METHODS: We evaluated the ICON and Acute Optic Neuritis Network (ACON) criteria for CRMP5-IgG+ON, using patients with late-onset (age ≥50 years) aquaporin-4-IgG-positive (AQP4-IgG+)-ON or myelin-oligodendrocyte glycoprotein antibody (MOG-IgG+)-ON for comparison. We developed the "CRMP score," based on typical CRMP5-IgG+ON clinical features, to guide CRMP5 antibody testing in ON.
RESULTS: The study included 17 patients with CRMP5-IgG+, 11 with AQP4-IgG+ON, and 13 with MOG-IgG+ON. Application of ICON criteria yielded no "definite ON" and 1 "probable ON" diagnosis among the 17 CRMP5-IgG+ cases, but definite ON diagnoses for 6 of 11 AQP4-IgG+ (55%, p = 0.003) and 7 of 13 MOG-IgG+ cases (54%, p = 0.001). ACON criteria yielded definite ON diagnoses for 2 (12%) CRMP5-IgG+ON, 10 (91%) of the AQP4-IgG+ON, and 13 (100%) of the MOG-IgG+ON (p < 0.001). A CRMP score ≥1 identified CRMP5-IgG+ON with a sensitivity of 88.2% and a specificity of 87.5%.
DISCUSSION: ICON and ACON criteria for ON diagnosis identified only a minority of CRMP5-IgG+ON cases; thus, we developed the "CRMP" score to aid their identification in clinical practice.